Trinity Biotech (TRIB) Amortization - Deferred Charges (2016 - 2024)
Historic Amortization - Deferred Charges for Trinity Biotech (TRIB) over the last 10 years, with Q4 2024 value amounting to -$4.3 million.
- Trinity Biotech's Amortization - Deferred Charges fell 14820.39% to -$4.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$16.6 million, marking a year-over-year decrease of 1402.83%. This contributed to the annual value of -$9.6 million for FY2024, which is 320.79% up from last year.
- According to the latest figures from Q4 2024, Trinity Biotech's Amortization - Deferred Charges is -$4.3 million, which was down 14820.39% from -$1.7 million recorded in Q4 2023.
- In the past 5 years, Trinity Biotech's Amortization - Deferred Charges ranged from a high of -$346000.0 in Q2 2021 and a low of -$8.3 million during Q2 2022
- In the last 5 years, Trinity Biotech's Amortization - Deferred Charges had a median value of -$1.2 million in 2020 and averaged -$2.3 million.
- In the last 5 years, Trinity Biotech's Amortization - Deferred Charges soared by 7161.61% in 2021 and then plummeted by 229884.39% in 2022.
- Trinity Biotech's Amortization - Deferred Charges (Quarter) stood at -$1.2 million in 2020, then crashed by 144.36% to -$3.0 million in 2021, then rose by 24.04% to -$2.3 million in 2022, then increased by 24.03% to -$1.7 million in 2023, then tumbled by 148.2% to -$4.3 million in 2024.
- Its last three reported values are -$4.3 million in Q4 2024, -$1.7 million for Q4 2023, and -$2.3 million during Q4 2022.